• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by argenx SE

    11/12/24 9:50:11 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARGX alert in real time by email
    SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.10 ARGENX SE COMMON STOCK Cusip #N0610Q109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #N0610Q109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 4,792,909 Item 6: 0 Item 7: 5,074,684 Item 8: 0 Item 9: 5,074,684 Item 11: 8.480% Item 12: HC Cusip #N0610Q109 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 5,074,684 Item 8: 0 Item 9: 5,074,684 Item 11: 8.480% Item 12: IN Item 1(a). Name of Issuer: ARGENX SE Item 1(b). Address of Issuer's Principal Executive Offices: INDUSTRIEPARK ZQIJNAARDE 7, BUILDING C B-9052 ZWIJNAARDE , C9 B-9052 BE Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: N0610Q109 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 5,074,684 (b) Percent of Class: 8.480% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 5,074,684 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ARGENX SE. No one other person's interest in the COMMON STOCK of ARGENX SE is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ARGENX SE at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Get the next $ARGX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARGX

    DatePrice TargetRatingAnalyst
    5/13/2025$680.00Neutral → Outperform
    Robert W. Baird
    3/17/2025Mkt Perform → Outperform
    Bernstein
    3/12/2025Sell → Hold
    Deutsche Bank
    1/17/2025Hold → Sell
    Deutsche Bank
    11/12/2024$697.00Peer Perform → Outperform
    Wolfe Research
    11/5/2024$715.00Sector Perform → Sector Outperform
    Scotiabank
    11/1/2024$515.00 → $650.00Outperform → Neutral
    Robert W. Baird
    11/1/2024Mkt Perform → Outperform
    William Blair
    More analyst ratings

    $ARGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • argenx upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded argenx from Neutral to Outperform and set a new price target of $680.00

      5/13/25 8:50:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx upgraded by Bernstein

      Bernstein upgraded argenx from Mkt Perform to Outperform

      3/17/25 7:23:02 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx upgraded by Deutsche Bank

      Deutsche Bank upgraded argenx from Sell to Hold

      3/12/25 7:20:57 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • argenx Announces Results of Annual General Meeting of Shareholders

      May 28, 2025 – 10:01 PM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced the results of its Annual General Meeting of shareholders held on May 27, 2025. 91.1% of the Company's share capital was represented at the Annual General Meeting. All items on the agenda received the required majority of votes in favor except for agenda item 5 (adoption of the remuneration policy). This agenda item received a 73.0% majority where a 75% majority was required. As part of the approved resolutions: The Company's 2024 remuneration report received a 76.7% majo

      5/28/25 4:01:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Reports First Quarter 2025 Financial Results and Provides Business Update

      $790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update. "We continue to execute on our bold innovation agenda, guided by our ‘V

      5/8/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx to Present at BofA Securities 2025 Health Care Conference

      May 6, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, and members of the management team will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation. About argenx argenx is a global immunology company committ

      5/6/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Financials

    Live finance-specific insights

    See more
    • argenx Reports First Quarter 2025 Financial Results and Provides Business Update

      $790 million in first quarter global product net sales First patients treated with VYVGART Hytrulo pre-filled syringe for self-injection in US and Germany CIDP global expansion with positive CHMP opinion for VYVGART-SC (vial and pre-filled syringe) in EU Management to host conference call today at 2:30 PM CET (8:30 AM ET) May 8, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update. "We continue to execute on our bold innovation agenda, guided by our ‘V

      5/8/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025

      May 1, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium           32 800 50 201France          

      5/1/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update

      $737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe for gMG, enabling launch in the EU; FDA PDUFA (gMG and CIDP) on track for April 10 10 Phase 3 and 10 Phase 2 studies across pipeline ongoing in 2025, positioning for next wave of growth Recognized one-time tax benefit of $725 million related to previously unrecognized deferred tax assets Management to host conference call today at 2:30 PM CET (8:30 AM ET) February 27, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering f

      2/27/25 1:00:00 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by argenx SE

      SC 13G/A - ARGENX SE (0001697862) (Subject)

      11/14/24 1:22:37 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by argenx SE

      SC 13G/A - ARGENX SE (0001697862) (Subject)

      11/12/24 9:50:11 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by argenx SE (Amendment)

      SC 13G/A - ARGENX SE (0001697862) (Subject)

      2/14/24 10:03:02 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    SEC Filings

    See more
    • SEC Form 6-K filed by argenx SE

      6-K - ARGENX SE (0001697862) (Filer)

      5/28/25 4:37:40 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by argenx SE

      6-K - ARGENX SE (0001697862) (Filer)

      5/8/25 6:39:56 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by argenx SE

      6-K - ARGENX SE (0001697862) (Filer)

      4/28/25 8:06:51 AM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ARGX
    Leadership Updates

    Live Leadership Updates

    See more
    • argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

      January 16, 2023 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration f

      1/16/23 1:30:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Appoints Ana Cespedes to Board of Directors

      December 12, 2022 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors. Ana Cespedes brings robust experience across a broad range of critical areas for commercialization and access, as well as for organizational effectiveness. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.

      12/12/22 4:01:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • argenx Appoints Camilla Sylvest to Board of Directors

      September 8, 2022 Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 6:30pm CET, Mrs. Camilla Sylvest was appointed as non-executive director to its Board of Directors. Mrs. Sylvest brings strong strategic and operational leadership in the scaling of global commercial pharmaceutical organizations with a specific focus on company culture and sustainability. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.arg

      9/8/22 2:10:00 PM ET
      $ARGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care